Lay media reporting of rosiglitazone risk: extent, messaging and quality of reporting

BACKGROUND: A meta-analysis suggested the use of rosiglitazone was associated with an increased risk for cardiovascular (CV) events. Rosiglitazone remained available for use as more definitive safety trials were ongoing. This issue was reported in the lay media. OBJECTIVE: To review lay media articl...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabi, Doreen M, Lewin, Adriane M, Brown, Garielle E, Edwards, Alun L, Johnson, Jeffrey A, Ghali, William A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727509/
https://www.ncbi.nlm.nih.gov/pubmed/19630978
http://dx.doi.org/10.1186/1475-2840-8-40

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727509/
https://www.ncbi.nlm.nih.gov/pubmed/19630978
http://dx.doi.org/10.1186/1475-2840-8-40

Ejemplares similares